1. A pharmaceutical composition comprising: (a) from about 3 to 20 wt.% (R) -7- [3-amino-4- (2,4,5-trifluorophenyl) butyryl] -3-trifluoromethyl-5, 6,7,8-tetrahydro-imidazo [1,5-a] pyrazine-1-carboxylic acid methyl ester or its pharmaceutically acceptable salt； (b) from about 25 to 94 wt.% Metformin or its salt, such as hydrochloride； (c) from about 0.1 to 10 wt.% a lubricant； and (d) from about 0 to about 35% by weight of a binding agent. The pharmaceutical composition of claim 1, further comprising one or more excipients selected from the group consisting of (a) a diluent, (b) a disintegrant, (c) a surfactant, (d) a moisturizing agent, and (e) an antioxidant. The pharmaceutical composition according to claim 1, containing: (a) from about 5 to 18 wt.% (K) -7- [3-amino-4- (2,4,5-trifluorophenyl) butyryl] -3-trifluoromethyl- 5,6,7,8-tetrahydro-imidazo [1,5-a] pyrazine-1-carboxylic acid methyl ester or its pharmaceutically acceptable salt； (b) from about 65 to 77 wt.% Metformin or its salt, such as hydrochloride； (c) from about 1 to 2 wt.% a lubricant； and (d) from about 4 to 9% by weight of a binding agent. The pharmaceutical composition according to claim 3, further comprising from about 0.5 to 1 wt.% Surfactant and / or from about 5 to 15 wt.% Diluent. The pharmaceutical composition according to claim 3, wherein the lubricant is magnesium stearate or sodium stearyl fumarate, and the binding agent is polyvinylpyrrolidone. The pharmaceutical composition according to claim 3, containing: (a) about 9 wt.% (R) -7- [3-amino-4- (2,4,5-trifluorophenyl) butyryl] -3-trifluoromethyl-5,6 , 7,8-tetrahydro-imidazo [1,5-a] pyrazine-1-carboxylic acid methyl ester or its pharmaceutically acceptable salt； (b) about 73 wt.% Metformin or its salt, t1. Фармацевтическая композиция, содержащая:(a) примерно от 3 до 20 масс.% (R)-7-[3-амино-4-(2,4,5-трифторфенил)-бутирил]-3-трифторметил-5,6,7,8-тетрагидро-имидазо[1,5-а]пиразин-1-карбоновой кислоты метилового эфира или его фармацевтически пр
